Advanced/Metastatic Solid Tumors research hub
12 indexed studies · 5 currently recruiting
- recruitingPHASE1
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
This study is looking at a new medicine called PF-08046876 for people with advanced cancers like bladder, lung, head & neck, oesophageal, or pancreatic cancer. It checks how safe the medicine is and how well it works. The medicine is given through a drip.
United States · Canada · China - recruitingPHASE3
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
This study is testing a new drug, firmonertinib, for advanced non-small cell lung cancer with specific genetic changes. It compares firmonertinib to existing treatments to see which works best and is safest for newly diagnosed patients.
United States · Australia · Canada - active not recruitingPHASE3
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
This study is testing a new drug, MRTX849 (adagrasib), for advanced lung cancer with a specific gene change (KRAS G12C). It compares it to a standard treatment, docetaxel, for people whose cancer has already been treated.
United States · Australia · Austria - active not recruitingPHASE3
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
This study compares a new drug, furmonertinib, at two different strengths, with standard chemotherapy for patients in the UK who have advanced non-small cell lung cancer with a specific genetic change called an EGFR exon 20 insertion mutation. It aims to see which treatment is more effective and safe as a first treatment.
United States · Australia · Brazil - recruitingPHASE2, PHASE3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
This study looks at a new drug called adagrasib, on its own and with another drug, pembrolizumab, for people with advanced lung cancer. It's for those with a specific gene change (KRAS G12C) who haven't had treatment yet.
United States · Argentina · Australia - active not recruitingPHASE2
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
This study is looking at new combinations of medicines for advanced lung cancer. It aims to see how well different immunotherapy treatments work together and how safe they are for patients. The goal is to find better ways to treat this type of lung cancer.
United States · Australia · France - active not recruitingPHASE2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
This study looks at a new drug, DS-1062a, for people with advanced lung cancer that has spread or can't be removed by surgery. We want to see how well it works and if it's safe for those who haven't responded to previous treatments.
France - recruiting
Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients with NSCLC
This study looks at people with a type of advanced lung cancer treated with immunotherapy (pembrolizumab). We want to understand why some people respond well to treatment and others don't, and why some have side effects. We'll examine tumour samples to find patterns that help predict these outcomes.
France - active not recruitingPHASE2, PHASE3
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
This study looks at a new drug, fianlimab, combined with cemiplimab, for advanced lung cancer. It aims to see if this combination works better than cemiplimab alone, studying side effects and how treatments affect quality of life.
United States · Australia · Canada - active not recruitingPHASE1
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
This early-stage study is testing a new drug, furmonertinib, for advanced lung cancer. It's for people whose cancer has specific genetic changes (EGFR or HER2 mutations) and has progressed after previous treatments. Researchers are looking at its safety and how well it works.
United States · Australia · Canada - recruitingPHASE3
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
This study compares a new drug called tepotinib with standard treatments for advanced lung cancer. It's for people whose cancer has a specific change (MET Exon 14 mutation) and has already been treated. The aim is to see if tepotinib works better to stop the cancer from growing.
France - ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1b/2, Open-label, Randomized Study of Vudalimab in Combination With Chemotherapy or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced Non-small Cell Lung Cancer
This study is testing new treatments for advanced non-small cell lung cancer. It combines a new medicine, vudalimab, or an existing one, pembrolizumab, with chemotherapy. Doctors will be looking at how safe and effective these combinations are for patients.
Netherlands · Belgium · Spain